Monitoring and predicting schizophrenia relapses using voice analysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop a novel approach for monitoring and predicting relapses in patients with schizophrenia by utilizing voice-based biomarkers. It involves conducting voice interviews and questionnaires through the CALLYOPE application, alongside measuring plasma antipsychotic concentrations via blood tests. The goal is to create a simple and cost-effective tool that can help in the early detection of symptoms and improve treatment adherence, ultimately reducing the risk of relapses and hospitalizations. The study focuses on patients diagnosed with schizophrenia who are stable and receiving specific antipsychotic treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Affiliated to a social security or other social protection scheme
* Diagnosed with schizophrenia according to the DSM-5 (code F20)
* Stable state without duration criteria
* Main treatment with risperidone or paliperidone, aripiprazole, olanzapine in oral or long-acting injectable form
* Complementary treatment with an antipsychotic for anxiolytic or sedative purposes: chlorpromazine, loxapine or cyamemazine
* Able to speak and read French
* Able to perform speech evaluations
* Able to answer questionnaires on smartphone
* May be under curatorship or guardianship
* Agreeing to participate in the study and with informed consent signed by the subject, as well as by the legal representative in the case of a person under curatorship or guardianship

Exclusion Criteria:

* Suffering from a pathology that impairs French
* Suffering from a neurological pathology: multiple sclerosis, Parkinson's disease, Huntington's disease or neurodegenerative disease
* Treatment with lithium salts
* Anti-epileptic treatment
* Participant in another study involving medication

Where it's running

• Groupe Hospitalo-Universitaire Paris Psychiatrie et Neurosciences, Paris
  Paris, Paris, France Recruiting
• Groupe Hospitalo-Universitaire Paris Psychiatrie & Neurosciences
  Paris, France Not yet recruiting

Study contacts

• Principal investigator: Pierre De Maricourt, Dr — GHU Paris Psychiatry & Neurosciences
• Study coordinator: Pierre De Maricourt, Dr
• Email: P.DEMARICOURT@ghu-paris.fr
• Phone: (0)1 45 65 86 91

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Lumateperone to improve motivation in patients with schizophrenia and psychosis

  This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.

  Recruiting Phase 3 Louisiana State University Health Sciences Center Shreveport · Shreveport, Louisiana · NCT06482554

• Examining the effects of combined therapy for schizophrenia

  This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.

  Recruiting at 2 sites University of Toronto · Scarborough Village, Ontario and 1 other locations · NCT05731414

• XEP527 in stable schizophrenia: safety and how it behaves in the body

  This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.

  Recruiting Phase 1 Novartis · Bentonville, Arkansas · NCT07908680

• Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations

  This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.

  Recruiting Ciusss de L'Est de l'Île de Montréal · Montreal, Quebec · NCT07902518

• Quality of life and safety in quetiapine use for schizophrenia or bipolar disorder

  This study looks at how patients with schizophrenia or bipolar disorder feel and stay safe when treated with quetiapine alone or with other antipsychotics.

  Recruiting Bosnalijek D.D · Sarajevo · NCT07858565

• Neuronavigated rTMS for treatment-resistant auditory hallucinations

  We are testing whether personalized neuronavigated inhibitory rTMS can reduce persistent auditory verbal hallucinations in adults who don’t respond to medication.

  Recruiting Psychiatric University Hospital, Zurich · Zurich · NCT07856368

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.